Mathes Company’s Biogen BIIB Stock Holding History

Mathes Company’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-1,600	Closed	-$387K	–	131
2016 Q2	$387K	Hold	1,600	–	–	0.23%	96
2016 Q1	$417K	Hold	1,600	–	–	0.25%	90
2015 Q4	$490K	Hold	1,600	–	–	0.28%	83
2015 Q3	$467K	Sell	1,600 -550	-26%	-$182K	0.31%	79
2015 Q2	$868K	Sell	2,150 -100	-4%	-$40.1K	0.46%	61
2015 Q1	$950K	Hold	2,250	–	–	0.49%	60
2014 Q4	$764K	Hold	2,250	–	–	0.4%	73
2014 Q3	$744K	Hold	2,250	–	–	0.37%	75
2014 Q2	$709K	Hold	2,250	–	–	0.35%	82
2014 Q1	$688K	Hold	2,250	–	–	0.37%	84
2013 Q4	$629K	Hold	2,250	–	–	0.34%	86
2013 Q3	$542K	Hold	2,250	–	–	0.52%	50
2013 Q2	$484K	Buy	+2,250	New	+$481K	0.53%	50

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Mathes Company's BIIB Position: Q3 2016 in Review

Mathes Company sold out of Biogen (BIIB) in Q3 2016, closing a stake of 1,600 shares — an estimated $387K sold.

Mathes Company first reported a position in BIIB in Q2 2013 and held it in 13 quarters. The position peaked at $950K in Q1 2015. 1,014 funds tracked by Wall St. Rank hold BIIB as of Q3 2016.

Mathes Company reported no remaining Biogen position as of Q3 2016 after selling out during the quarter.
Mathes Company sold 1,600 Biogen shares in Q3 2016, an estimated $387K.
Mathes Company first reported a position in Biogen in Q2 2013 and held it in 13 quarters.
Mathes Company's Biogen position peaked at $950K in Q1 2015.
1,014 funds tracked by Wall St. Rank held Biogen as of Q3 2016.

Based on Mathes Company's 13F filing for Q3 2016, filed 31 Oct 2016.